In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $1.3 in the prior trading day, Opko Health Inc (NASDAQ: OPK) closed at $1.29, down -0.77%. In other words, the price has decreased by -$0.77 from its previous closing price. On the day, 2.3 million shares were traded. OPK stock price reached its highest trading level at $1.3015 during the session, while it also had its lowest trading level at $1.27.
Ratios:
Our goal is to gain a better understanding of OPK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.32 and its Current Ratio is at 3.70. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.28.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 21 ’25 when FROST PHILLIP MD ET AL bought 580,000 shares for $1.33 per share. The transaction valued at 768,807 led to the insider holds 216,706,448 shares of the business.
FROST PHILLIP MD ET AL bought 580,000 shares of OPK for $771,328 on Nov 20 ’25. The CEO & Chairman now owns 216,126,448 shares after completing the transaction at $1.33 per share. On Nov 19 ’25, another insider, FROST PHILLIP MD ET AL, who serves as the CEO & Chairman of the company, bought 580,000 shares for $1.31 each. As a result, the insider paid 759,115 and bolstered with 215,546,448 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OPK now has a Market Capitalization of 1023979776 and an Enterprise Value of 973782656. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.54 while its Price-to-Book (P/B) ratio in mrq is 0.76. Its current Enterprise Value per Revenue stands at 1.517 whereas that against EBITDA is -8.408.
Stock Price History:
The Beta on a monthly basis for OPK is 1.38, which has changed by -0.12244898 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, OPK has reached a high of $2.04, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -5.52%, while the 200-Day Moving Average is calculated to be -8.14%.
Shares Statistics:
The stock has traded on average 2.55M shares per day over the past 3-months and 3734940 shares per day over the last 10 days, according to various share statistics. A total of 768.70M shares are outstanding, with a floating share count of 391.08M. Insiders hold about 49.06% of the company’s shares, while institutions hold 27.66% stake in the company. Shares short for OPK as of 1765756800 were 32577197 with a Short Ratio of 12.80, compared to 1763078400 on 33814574. Therefore, it implies a Short% of Shares Outstanding of 32577197 and a Short% of Float of 7.3999999999999995.
Earnings Estimates
At present, 1 analysts are actively evaluating the performance of Opko Health Inc (OPK) in the stock market.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.08 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.3 and -$0.35 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is -$0.31, with 1 analysts recommending between -$0.31 and -$0.31.
Revenue Estimates
7 analysts predict $139.76M in revenue for. The current quarter. It ranges from a high estimate of $147.4M to a low estimate of $137M. As of. The current estimate, Opko Health Inc’s year-ago sales were $183.6MFor the next quarter, 7 analysts are estimating revenue of $130.8M. There is a high estimate of $134.8M for the next quarter, whereas the lowest estimate is $127.9M.
A total of 7 analysts have provided revenue estimates for OPK’s current fiscal year. The highest revenue estimate was $605.8M, while the lowest revenue estimate was $595.04M, resulting in an average revenue estimate of $598.11M. In the same quarter a year ago, actual revenue was $713.1MBased on 7 analysts’ estimates, the company’s revenue will be $581.01M in the next fiscal year. The high estimate is $648.29M and the low estimate is $535M.
